Skip to main content

Table 1 Key model parameters for describing the effect of treatment on transmission

From: Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment

Description Symbol Value(s) References
Untreated infections
 Mean duration of state (days)    [17]
  D (clinical disease) dD 5  
  A (asymptomatic) dA 195  
  U (submicroscopic) dU 84  
 Probability of human-to-mosquito transmission per mosquito bite from individuals in state    [17]
  D (clinical disease) cD 0.0868596  
  A (asymptomatic) cA cD > cA > cU varies by immunity  
  U (submicroscopic) cU 0.0023444  
 Total infectivity over the infectious period in untreated, initially symptomatic infections Otot cDdD + cAdA + cUdU
 Proportion of infections which develop symptoms φ 0.00038–0.81 (immunity-dependent)  
Treated infections
 Drug efficacy: probability the drug eventually clears parasites peff 0.97 [6]
 % reduction Otot in total infectivity over the infectious period achieved by treatment with:    [17]
  SP Ored 79.1%  
  ACT   92.7%  
  ACT + primaquine   100%  
 Mean duration of state    [17]
  PDT, PAU, or PS (prophylaxis) dP 3, 30, 60  
  T dT 5  
 Probability of human-to-mosquito transmission per mosquito bite from individuals in state    This paper
  T (will soon receive treatment) cT cD  
  PDT (prophylaxis) cPDT Otot * (1 − Ored/100)/dP  
  PAU (prophylaxis) cPAU cA * cPDT/cD  
 MDA coverage: proportion of individuals receiving MDA fMDA 0.8
 Case management coverage: proportion of cases treated fT 0.4–1
  1. A full parameter list is given in [17]